Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT01231594
Title	A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	GlaxoSmithKline
Indications	Advanced Solid Tumor
Therapies	Dabrafenib Trametinib
Age Groups:	adult \| senior
Covered Countries	USA \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS